Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Citations
366 citations
260 citations
252 citations
186 citations
Cites background or methods from "Clinical Pharmacogenetics Implement..."
...DPYD The CPIC provides fluoropyrimidine dosing recommendations for normal/high, intermediate, and deficient dihydropyrimidine dehydrogenase activity phenotypes based on DPYD genotypes.(14) In contrast, the DPWG uses an activity-score (AS) to accommodate the increasing number of DPYD allelic variants and their difference in function (See Table 3)....
[...]
...In contrast, the CPIC mentions this variant without assigned status, similar to the IVS10-15TC variant.(14) CYP2D6 Both consortia classify the CYP2D6*36 allele as a variant allele; however, there is a difference in the interpretation of the functionality of this allele between the two consortia....
[...]
...The CPIC reports that there is a clear association of the *13 allele with reduced clearance of capecitabine and 5-fluorouracil in addition to evidence from case reports.(14) In contrast, the DPWG concludes that the evidence supporting a decreased activity of the *13 allele is limited and only described in case reports....
[...]
...DPYD 1 fluoropyrimidines As mentioned previously, the DPWG uses an AS for DPYD whereas the CPIC uses phenotypes of normal/high, intermediate, and deficient activity (soon to be changed to normal, intermediate, and poor metabolizers, respectively, in the next DPYD guideline update based on the results of the CPIC term standardization project).(14,51) The gene activity model scores alleles with a reduced function as 0....
[...]
151 citations
References
877 citations
848 citations
847 citations
485 citations
388 citations